Global Neurogenomics Market Size Projected to Reach $2.6 Billion During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Neurogenomics Market Over The Five-Year Period 2025–2029?

The neurogenomics market has observed substantial expansion in recent years. It is anticipated to expand from $1.31 billion in 2024 to $1.50 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 15.0%. The past growth in this market stems from factors such as a heightened demand for genetic testing in neurological disorders, expanded research exploring brain-behavior-genome links, an increasing incidence of neurodegenerative diseases, greater funding directed towards neuroscience research, and an expanding collection of biobanks and genomic databases.

The neurogenomics market is projected to undergo significant expansion in the upcoming years, with its size expected to reach $2.60 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 14.7%. This anticipated growth can be linked to several factors, including a heightened interest in personalized treatments for mental health conditions, the expanding availability of direct-to-consumer neurogenetic testing, increasing adoption rates of multi-omics approaches, the rise in precision neurology initiatives, and the greater use of targeted therapies. Prominent trends throughout this period are set to include the advancement of artificial intelligence-powered genomic analytics, the creation of non-invasive diagnostic platforms, the integration of multi-omics methodologies, the incorporation of genomics into precision neurology practices, and breakthroughs in neurodegenerative disease modelling.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25845&type=smp

Which Major Market Drivers Are Shaping The Future Of The Neurogenomics Market?

The increasing occurrence of neurological conditions is anticipated to fuel the expansion of the neurogenomics market in the future. These disorders encompass medical ailments impacting the brain, spinal cord, or nerves, resulting in indications like muscle weakness, seizures, discomfort, or issues with cognition. The growing incidence of neurological conditions largely stems from lifestyle elements including inadequate diet, insufficient physical exercise, prolonged stress, and heightened exposure to environmental pollutants. Neurogenomics offers enhanced insight into the genetic foundations of brain operation and impairment, facilitating the determination of etiologies, more effective diagnosis, and specific therapeutic interventions for neurological conditions. As an illustration, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, indicated that around 6.7 million Americans aged 65 and older were affected by Alzheimer’s dementia, with projections showing this figure reaching 13.8 million by 2060. Consequently, the escalating occurrence of neurological ailments is propelling the expansion of the neurogenomics market.

How Is The Neurogenomics Market Segmented?

The neurogenomics market covered in this report is segmented –

1) By Offering: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Software And Services

2) By Application: Variant Discovery, Research Applications, Target Identification, Transcription Factor Binding Analysis, Functional Studies, Clinical Applications

3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Ribonucleic Acid Sequencing

2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction

3) By Microarray: Deoxyribonucleic Acid Microarray, Ribonucleic Acid Microarray, Protein Microarray

4) By Software And Services: Data Analysis And Interpretation Software, Genomic Data Management Tools, Custom Services, Cloud-Based Platforms And Reporting Tools

Which Key Trends Are Expected To Influence The Neurogenomics Market In The Coming Years?

Leading companies active in the neurogenomics market are concentrating on creating sophisticated solutions, such as whole genome sequencing platforms, to improve the diagnosis and understanding of intricate neurological disorders. Whole genome sequencing platforms are instruments employed to examine an individual’s complete DNA sequence, assisting in pinpointing genetic factors connected to neurological disorders. For example, in April 2023, Centogene N.V., a Germany-based firm involved in rare disease diagnosis and research, unveiled CentoGenome, described as the world’s most extensive whole-genome sequencing (WGS) solution for identifying rare and neurodegenerative diseases. This platform incorporates PCR-free technology to enable high-quality, unbiased sequencing across complex genetic regions. It boosts variant detection using an advanced bioinformatics pipeline and expert interpretation, succeeding in identifying almost all disease-causing variants in a single test. Moreover, it delivers integrated, lifelong diagnostic support, featuring free variant reclassification and confirmatory testing as new scientific insights become accessible.

Which Key Players Are Driving Competition In The Neurogenomics Market?

Major companies operating in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc, Vigil Neuroscience Inc., PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., Neurogene.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neurogenomics-global-market-report

How Does The Neurogenomics Market Perform Across Key Geographic Regions?

North America was the largest region in the neurogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neurogenomics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25845&type=smp

Browse Through More Reports Similar to the Global Neurogenomics Market 2025, By The Business Research Company

Neurogenetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Genomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Neurological Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795